Viveve Treatment in Atlanta
for vaginal rejuvenation (formerly called "Geneveve")
The VIVEVE Treatment is an unrivaled and long-lasting solution for vagina issues, especially lubrication, vaginal tightness, vaginal laxity, sexual dysfunction, vaginal atrophy, and urinary incontinence. This unique non-surgical treatment, formerly known as Genevieve, gently and painlessly improves the structural integrity of the vagina and urethra. With the Viveve treatment at our Atlanta clinic, you can rewind the clock of childbirth, age, and hormonal changes which had taken a toll on your vaginal health - in just one treatment.
Single Treatment;No DownTime
The Viveve System is a patented, cryogen-cooled monopolar, radiofrequency (CMRF) energy delivery system. The system safely and consistently delivers 90J/cm2 of energy to the lamina propria and the muscularis responsible for creating collagen. At the same time, the controlled cooling protects the vagina mucosal surface from damage and lowers the resistance of the epithelial layer. Therefore energy is safely dispersed to the targeted region without any damage to the paravaginal organs and tissues.
The Viveve treatment involves a small probe inserted into the vagina to emit the radiofrequency waves and cryogen cooling simultaneously. The heat from the radiofrequency waves drives the protection of new collagen, enabling the vagina to restore itself naturally. Viveve is approved for stress and urinary incontinence, vagina laxity, and sexual dysfunction around the world. Viveve is used off-label in the U.S. The company is currently going through regulatory procedures to get approval for treating these conditions. This patented and gentle process is less intrusive than many other treatments. Patients will only require one treatment of about 45 to 75 minutes to enjoy long-lasting results.
Viveve Medical Inc. developed the Viveve treatment for restoring and remodeling vaginal health and tissues. It is the first company in the women's intimate health space to have undergone and completed a randomized, blinded placebo-controlled study. It is dedicated to creating new solutions that improve women's quality of life and well-being. Viveve is currently the only device undergoing FDA approval for the treatment of sexual function. However, the patented technology has received international regulatory approval and clearances in over 50 countries. In a study following the treatment for sexual function and vaginal laxity, patients reported positive outcomes. Studies have equally shown that patients achieve a 50% reduction in 1-pad weight at six months, and 69% have achieved a reduction in stress urinary incontinence. On average, 73% of patients witnessed sustained results for at least 12 months.